Fibrinogen-to-Albumin Ratio for Predicting Adverse Perinatal Outcomes in Preeclampsia

A dual-center retrospective cohort study of 924 preeclamptic patients evaluated the incremental prognostic value of the fibrinogen-to-albumin ratio (FAR). The extended model incorporating FAR achieved an area under the curve (AUC) of 0.888 in the training cohort and 0.856 in external validation. Author Xiaoyun Chen published the study on figshare under a CC-BY-4.0 license in May 2026.

Use Cases

• Validate the FAR biomarker as a predictor for a composite adverse perinatal outcome (CAPO) based on the study's defined clinical events.
• Benchmark new prognostic models against the reported base model with an AUC of 0.852 and the FAR-extended model.
• Guide anesthesia and perioperative care decisions using the identified FAR cutoff of 0.135, which suggests coagulopathy and systemic inflammation.

Strengths

• Dataset includes 924 patient records from two tertiary referral hospitals, providing a substantial clinical cohort.
• Model performance was rigorously assessed with internal and external validation cohorts (n=204 and n=244), and metrics like AUC, NRI, and IDI are reported.
• The study defines a clear composite outcome (CAPO) encompassing eight specific adverse perinatal events.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment for direct data analysis.
• As a retrospective cohort study, the data may reflect biases inherent to the specific hospitals and time periods of collection.

Provenance

Source

figshare, author Xiaoyun Chen.

Collection Method

Dual-center retrospective cohort study.

Freshness

Last updated 2026-05-29 04:50:31.

Geography

Data from two tertiary referral hospitals; specific locations unknown.